We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
-5.2%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$642M
AUM Growth
-$8.55M
Cap. Flow
+$84.4M
Cap. Flow %
13.15%
Top 10 Hldgs %
47.56%
Holding
90
New
25
Increased
18
Reduced
19
Closed
18

Top Buys

Rank Stock Value
1
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$30M
2
UTHR icon
United Therapeutics
UTHR
+$20.1M
3
FLXN
Flexion Therapeutics, Inc.
FLXN
+$13M
4
EPIX
ESSA Pharma
EPIX
+$10M
5
ORGO icon
Organogenesis Holdings
ORGO
+$9.94M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$18.7M
2
SKIN icon
SkinHealth Systems
SKIN
+$16.1M
3
BCAB icon
BioAtla
BCAB
+$10.9M
4
NVCR icon
NovoCure
NVCR
+$10.8M
5
ITMR
Itamar Medical Ltd. American Depository Shares
ITMR
+$7.74M

Sector Composition

Rank Sector Weight
1 Healthcare 91.89%
2 Financials 1.01%
3 Consumer Staples 0.82%
4 Real Estate 0.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
YMAB
26
DELISTED
Y-mAbs Therapeutics
YMAB
$7.58M 1.18%
265,700
+121,400
+84% +$3.83M
INSP icon
27
Inspire Medical Systems
INSP
$1.85B
$7.21M 1.12%
30,950
+9,400
+44% +$1.96M
KRYS icon
28
Krystal Biotech
KRYS
$9.61B
$6.55M 1.02%
125,529
+58,000
+86% +$3.43M
CTSO icon
29
Cytosorbents Corp
CTSO
$23.7M
$6.5M 1.01%
+800,000
New +$6.5M
ANGO icon
30
AngioDynamics
ANGO
$628M
$6.29M 0.98%
+242,525
New +$6.49M
LKFT
31
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.73B
$6.07M 0.95%
+115,300
New +$6.84M
ITMR
32
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$5.46M 0.85%
180,839
-350,000
-66% -$7.74M
SKIN icon
33
SkinHealth Systems
SKIN
$91.4M
$5.25M 0.82%
201,994
-732,322
-78% -$16.1M
SLGC
34
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$5.23M 0.82%
+422,243
New +$4.76M
VNDA icon
35
Vanda Pharmaceuticals
VNDA
$321M
$5.12M 0.8%
+298,600
New +$5.23M
TVTX icon
36
Travere Therapeutics
TVTX
$5.21B
$5.11M 0.8%
+210,815
New +$3.87M
EOLS icon
37
Evolus
EOLS
$403M
$4.9M 0.76%
642,934
+62,934
+11% +$651K
AVIR icon
38
Atea Pharmaceuticals
AVIR
$376M
$4.12M 0.64%
+117,600
New +$3.26M
ASMB icon
39
Assembly Biosciences
ASMB
$524M
$3.9M 0.61%
93,500
– –
PVLA
40
Palvella Therapeutics
PVLA
$2.18B
$3.83M 0.6%
+9,250
New +$3.22M
CMPS
41
Compass Pathways
CMPS
$1.59B
$3.82M 0.59%
127,743
– –
PCRX icon
42
Pacira BioSciences
PCRX
$1.09B
$3.7M 0.58%
+66,000
New +$3.8M
DALS
43
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
$3.44M 0.54%
+350,000
New +$3.46M
ARNA
44
DELISTED
Arena Pharmaceuticals Inc
ARNA
$3.38M 0.53%
+56,800
New +$3.36M
XENE icon
45
Xenon Pharmaceuticals
XENE
$6.19B
$3.3M 0.51%
215,697
-18,000
-8% -$313K
INBX
46
DELISTED
Inhibrx, Inc. Common Stock
INBX
$3.26M 0.51%
97,979
-144,810
-60% -$4.41M
FDMT icon
47
4D Molecular Therapeutics
FDMT
$536M
$3.26M 0.51%
120,900
+20,100
+20% +$573K
NVCR icon
48
NovoCure
NVCR
$1.89B
$3.17M 0.49%
27,275
-71,700
-72% -$10.8M
LUNG icon
49
Pulmonx
LUNG
$87M
$3.15M 0.49%
87,612
+2,362
+3% +$92.9K
VIVO
50
DELISTED
Meridian Bioscience Inc
VIVO
$3.14M 0.49%
+163,000
New +$3.25M
1
2
3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return
Q
QVR San Francisco, California $2.49B AUM 48.58% 1-Year Est. Return
SIM
Stratos Investment Management Beachwood, Ohio $2.49B AUM 17.24% 1-Year Est. Return

Soleus Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Soleus Capital Management held 90 positions worth $642M, down 1.3% from $650M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Soleus Capital Management deployed $84.4M of net new capital in Q3 2021, opening 25 new positions and adding to 18 existing holdings. Its largest new stake was DICE Therapeutics, Inc. Common Stock: 879,903 shares worth $28.8M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 91% a quarter earlier, followed by Financials and Consumer Staples.

On the sell side, the largest reduction was IVERIC bio, Inc. Common Stock, an estimated $18.7M trimmed.

  • Soleus Capital Management's largest Q3 2021 buy was DICE Therapeutics, Inc. Common Stock: 879,903 shares worth $28.8M.
  • Soleus Capital Management added most to ESSA Pharma in Q3 2021, an estimated $10M increase.
  • Soleus Capital Management's biggest Q3 2021 reduction was IVERIC bio, Inc. Common Stock, cutting an estimated $18.7M.
  • Soleus Capital Management fully exited MiMedx Group in Q3 2021, selling an estimated $4.03M.
  • Soleus Capital Management's ten largest holdings make up 48% of its $642M portfolio in Q3 2021.
  • Soleus Capital Management opened 25 new positions and closed 18 in Q3 2021.
  • Soleus Capital Management's portfolio value fell 1.3% quarter-over-quarter to $642M.

Based on Soleus Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.